Evidence map›Paper›PMID 27689696›Full record

ArticlePLoS pathogens2016

High Resolution Mapping of Bactericidal Monoclonal Antibody Binding Epitopes on Staphylococcus aureus Antigen MntC.

Alexey V Gribenko, Kevin Parris, Lidia Mosyak, Sheng Li, Luke Handke, Julio C Hawkins, Elena Severina, Yury V Matsuka, Annaliesa S Anderson

Abstract read
In one paragraph

Article in PLoS pathogens, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Review
  3. Performance of a Four-AntigenMicroorganisms · 2021
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Two Vaccines formSphere · 2018
    Article
  10. Article
  11. Review
  12. Optimization of Feasibility Stage for Hydrogen/Deuterium Exchange Mass Spectrometry.Journal of the American Society for Mass Spectrometry · 2018
    Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alexey V GribenkoPfizer Vaccine Research and Development, Pearl River, New York, United States of America.
Kevin ParrisPfizer Protein Engineering and Production, Cambridge, Massachusetts, United States of America.
Lidia MosyakPfizer Protein Engineering and Production, Cambridge, Massachusetts, United States of America.
Sheng LiDepartment of Medicine, University of California at San Diego, La Jolla, California, United States of America.
Luke HandkePfizer Vaccine Research and Development, Pearl River, New York, United States of America.
Julio C HawkinsPfizer Vaccine Research and Development, Pearl River, New York, United States of America.
Elena SeverinaPfizer Vaccine Research and Development, Pearl River, New York, United States of America.
Yury V MatsukaPfizer Vaccine Research and Development, Pearl River, New York, United States of America.
Annaliesa S AndersonPfizer Vaccine Research and Development, Pearl River, New York, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Staphylococcus aureus manganese transporter protein MntC is under investigation as a component of a prophylactic S.aureus vaccine. Passive immunization with monoclonal antibodies mAB 305-78-7 and mAB 305-101-8 produced using MntC was shown to significantly reduce S. aureus burden in an infant rat model of infection. Earlier interference mapping suggested that a total of 23 monoclonal antibodies generated against MntC could be subdivided into three interference groups, representing three independent immunogenic regions. In the current work binding epitopes for selected representatives of each of these interference groups (mAB 305-72-5 - group 1, mAB 305-78-7 - group 2, and mAB 305-101-8 - group 3) were mapped using Hydrogen-Deuterium Exchange Mass Spectrometry (DXMS). All of the identified epitopes are discontinuous, with binding surface formed by structural elements that are separated within the primary sequence of the protein but adjacent in the context of the three-dimensional structure. The approach was validated by co-crystallizing the Fab fragment of one of the antibodies (mAB 305-78-7) with MntC and solving the three-dimensional structure of the complex. X-ray results themselves and localization of the mAB 305-78-7 epitope were further validated using antibody binding experiments with MntC variants containing substitutions of key amino acid residues. These results provided insight into the antigenic properties of MntC and how these properties may play a role in protecting the hostagainst S. aureus infection by preventing the capture and transport of Mn2+, a key element that the pathogen uses to evade host immunity.

Identifiers

PMID27689696
PMCPMC5045189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.